27 research outputs found
How COVID-19 has impacted the preference for mode of delivery of post-graduated training courses in West Africa
Voices in the wilderness: how exclusionist article processing charge policies of academic journals underscore what is wrong with global health.
Comment - No abstract available
Trends in clinical trial registration in sub-Saharan Africa between 2010 and 2020: a cross-sectional review of three clinical trial registries.
OBJECTIVE: Prospective registration of clinical trials is an ethical, scientific, and legal requirement that serves several functions, including minimising research wastage and publication bias. Sub-Saharan Africa (SSA) is increasingly hosting clinical trials over the past few years, and there is limited literature on trends in clinical trial registration and reporting in SSA. Therefore, we set out to determine the trends in clinical trials registered in SSA countries between 2010 and July 2020. METHODS: A cross-sectional study design was used to describe the type of clinical trials that are conducted in SSA from 1 January 2010 to 31 July 2020. The registries searched were ClinicalTrials.gov (CTG), the Pan African Clinical Trials Register (PACTR), and the International Standard Randomized Controlled Trial Number (ISRCTN). Data were extracted into Excel and imported into STATA for descriptive analysis. RESULTS: CTG had the highest number of registered trials at 2622, followed by PACTR with 1501 and ISRCTN with 507 trials. Trials were observed to increase gradually from 2010 and peaked at 2018-2019. Randomised trials were the commonest type, accounting for at least 80% across the three registries. Phase three trials investigating drugs targeted at infections/infestations were the majority. Few completed trials had their results posted: 58% in ISRCTN and 16.5% in CTG, thus suggesting reporting bias. CONCLUSION: Despite the gradual increase in clinical trials registered during the period, recent trends suggest a drop in the number of trials registered across the region. Strengthening national and regional regulatory capacity will improve clinical trial registration and minimise reporting bias in completed clinical trials
COVID-19 in Nigeria: Implications for Management of Related Co-morbidities, Prevalent Public Health Challenges, and Future Epidemic Preparedness
The Coronavirus Disease-2019 (COVID-19) pandemic is now well-established in Africa with cases reported from all countries on the continent. Despite the significant progress that has been made in the response to the pandemic in Nigeria, relative to the period of Ebola epidemic, the currently reported number of COVID-19 cases are likely under-estimates of the true number of cases. This is attributable to restricted testing capacity due to limited technical, infrastructural, financial, and logistical capacity to rapidly scale-up testing. In this article, we explore the impact of the COVID-19 pandemic on management of related co-morbidities and the major prevalent public health challenges, including mental health, in Nigeria, Africa’s most populous country. We also discuss the most current knowledge about candidate vaccines for the control of the novel coronavirus (SARS-CoV-2) strain. The interactions between COVID-19 and the endemic public health challenges in Nigeria further highlight the linkage between infectious diseases and poverty, and emphasise the need for a sustained increase in investments in the general public health system that is geared toward achieving Universal Health Coverage in Nigeria
Tracking coverage, dropout and multidimensional equity gaps in immunisation systems in West Africa, 2000-2017.
BACKGROUND: Several West African countries are unlikely to achieve the recommended Global Vaccine Action Plan (GVAP) immunisation coverage and dropout targets in a landscape beset with entrenched intra-country equity gaps in immunisation. Our aim was to assess and compare the immunisation coverage, dropout and equity gaps across 15 West African countries between 2000 and 2017. METHODS: We compared Bacille Calmette Guerin (BCG) and the third dose of diphtheria-tetanus-pertussis (DTP3) containing vaccine coverage between 2000 and 2017 using the WHO and Unicef Estimates of National Immunisation Coverage for 15 West African countries. Estimated subregional median and weighted average coverages, and dropout (DTP1-DTP3) were tracked against the GVAP targets of ≥90% coverage (BCG and DTP3), and ≤10% dropouts. Equity gaps in immunisation were assessed using the latest disaggregated national health survey immunisation data. RESULTS: The weighted average subregional BCG coverage was 60.7% in 2000, peaked at 83.2% in 2009 and was 65.7% in 2017. The weighted average DTP3 coverage was 42.3% in 2000, peaked at 70.3% in 2009 and was 61.5% in 2017. As of 2017, 46.7% of countries (7/15) had met the GVAP targets on DTP3 coverage. Average weighted subregional immunisation dropouts consistently reduced from 16.4% in 2000 to 7.4% in 2017, meeting the GVAP target in 2008. In most countries, inequalities in BCG, and DTP3 coverage and dropouts were mainly related to equity gaps of more than 20% points between the wealthiest and the poorest, high coverage regions and low coverage regions, and between children of mothers with at least secondary education and those with no formal education. A child's sex and place of residence (urban or rural) minimally determined equity gaps. CONCLUSIONS: The West African subregion made progress between 2000 and 2017 in ensuring that its children utilised immunisation services, however, wide equity gaps persist
Exploring the perspectives of members of international tuberculosis control and research networks on the impact of COVID-19 on tuberculosis services: a cross sectional survey.
BACKGROUND: The COVID-19 pandemic has caused major disruption to healthcare services globally and has impacted on tuberculosis (TB) patients and TB diagnosis and treatment services both in low- and high-income countries. We therefore explored the perspectives of members of regional and international TB control and research networks to further understand TB service disruptions and compared the experiences of members from West African and European countries. METHODS: This cross-sectional, explorative descriptive study was conducted from May to July 2020 using an open online survey with target respondents from both West African and European countries. The survey comprised discrete questions exploring challenges faced with TB screening, diagnosis, treatment, prevention, and changes implemented. Additionally, respondents were asked to provide recommendations for remedial actions. RESULTS: We analysed responses from 124 respondents based in 29 countries located in Europe and West Africa. About half of the respondents reported challenges in delivering routine TB services during the COVID-19 pandemic, with over one third reporting having some form of guidance issued regarding maintaining delivery of routine TB services. Respondents emphasised the need for strengthening TB services especially in light of COVID-19 pandemic. Considerable similarities were found between the challenges experienced by TB professionals in both West African and European settings. Responses also highlighted the hidden challenges faced in some countries prior to the COVID-19 pandemic, especially in some West African settings where staff shortages and laboratory issues predated COVID-19. CONCLUSIONS: TB control and research professionals in West African and European settings experienced similar challenges to the delivery of TB diagnosis and treatment services due to the COVID-19 pandemic, and highlighted the need for clear communication of guidelines, prioritisation of routine TB service delivery, ongoing health education, and possible integration of TB and COVID-19 services to ensure that TB services are more resilient against the impact of the pandemic
Reduced health-related quality of life after tuberculosis treatment in Gambian children
Oral presentation at the West African College of Physicians 44th & 45th Annual General and Scientific Meetin
The Health Care Professional Antibiotic Resistance Awareness Scale v1: report on development and testing
As the threat of antimicrobial resistance (AMR) grows, multilateral bodies are mobilising support for national and global action. A cornerstone of action plans is to increase awareness of resistance amongst different groups, including human and animal health care professionals. Understanding current levels of awareness is required for targeting interventions as well as for assessing change. This project designed a questionnaire tool to assess awareness of AMR amongst HCPs in different low- and middle-income countries. The content of the questionnaire was developed through qualitative research, review of literature and existing tools, and expert consultations in a range of settings. The resulting set of 88 questions – to assess awareness, practice and context – were then piloted from April to September 2018 with human and animal health care professionals in six countries. A total of 1091 participants completed the survey online or on paper – 43 in Peru (human HCPs, in Spanish), 122 in Peru (animal HCPs, in Spanish), 112 in Nigeria (human HCPs, in English), 106 in Ghana (human HCPs, in English), 124 in Tanzania (human HCPs, in English) 40 in Tanzania (human HCPs, in KiSwahili), 253 in Vietnam (human HCPs, in Vietnamese), 183 in Vietnam (animal HCPs, in Vietnamese), and 43 in Thailand (animal HCPs, in Thai). The 49 items in the questionnaire intended to capture awareness and awareness-in-practice were evaluated using the psychometric analytic approach of Rasch Measurement Theory. A total of 23 items were retained after less well-performing items were removed, and the Rasch analysis was then re-run. The 23 items constitute the Health Care Professional (HCP) Antibiotic Resistance (ABR) Awareness Scale v1, to include four domains: awareness of mechanisms of antibiotic resistance; the ways antibiotic use drives antibiotic resistance; the ways antibiotic resistant infections can be transmitted and controlled; and how antibiotic resistance can be recognised. Overall, the 23-item HCP ABR Awareness Scale v1 performed sufficiently well to be used within certain parameters – in the languages tested and to perform within-country rather than between-country comparisons. It is also recommended that awareness is measured alongside practice and context indicators to capture practice in relation to antibiotic use as well as contextual factors that may explain levels of awareness
Childhood TB sequel: evaluating respiratory function after treatment for pulmonary tuberculosis in a prospective cohort of Gambian children - a study protocol.
BACKGROUND: 1.2Â million children under 15 years are estimated to have developed tuberculosis (TB) in 2021. 85% of paediatric patients achieve successful treatment outcomes if treated for the first episode of TB. However, despite so-called successful treatment, TB leaves many survivors with permanently destroyed or damaged lungs. Data from prospective paediatric cohorts to establish the burden and evolution of post-TB lung disease (PTLD) are still absent. The Childhood TB Sequel study aims to describe respiratory consequences associated with pulmonary TB in Gambian children, describe the evolution of these sequelae, and determine associated epidemiological risk factors. METHODS: We aim to recruit up to 80 subjects aged 19 years and below who have recently completed treatment for pulmonary TB. Recruitment started in April 2022 and is expected to continue until June 2024. Clinical assessment, chest X-ray, and comprehensive lung function assessment are carried out at treatment completion and again six and 12 months later. DISCUSSION: The Childhood TB Sequel study will address existing research gaps to enhance our knowledge and understanding of the burden of PTLD in Gambian children. The study will also contribute to formulating a plan for post-TB evaluation and long-term follow-up strategies. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05325125, April 13, 2022